News | June 10, 2022
GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer
Healthcare is timely and personal – and its delivery should be too
Healthcare is timely and personal – and its delivery should be too
Bayer now present in four of the largest biotechnology hubs in the United States
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Based on a post hoc analysis, fewer required respiratory interventions
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Subscribe To Our Newsletter & Stay Updated
